hepatology
Madrigal sings praises of NASH drug resmetirom
Phil Taylor
hepatology, Madrigal Pharmaceuticals, NASH
0 Comment
Bayer trumpets $1bn CRISPR deal with Mammoth Bio
Phil Taylor
Bayer, CRISPR, gene editing, hepatology, Mammoth Biosciences, partnering
0 Comment
Ipsen places €480m bet on Genfit’s liver drug elafibranor
Phil Taylor
elafibranor, Genfit, hepatology, Ipsen, partnering, primary biliary cholangitis
0 Comment
Intercept’s travails continue as it pulls NASH drug filing in EU
Phil Taylor
EU, hepatology, Intercept Pharmaceuticals, NASH, regulatory
0 Comment
Digital health firm ChronWell raises $6m for liver disease toolkit
Phil Taylor
ChronWell, digital, digital health, hepatology, LIVErHEALTHY, NASH, remote care
0 Comment
Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit
Phil Taylor
Diabetes, Dicerna, gene silencing, hepatology, NASH, Novo Nordisk, RNAi
0 Comment
Gilead and Novo plot next steps after trial data from NASH combo
Richard Staines
Gilead, hepatology, NASH, Novo Nordisk, semaglutide
0 Comment